24 June 2022 in Journal of Clinical Epidemiology
15 December 2025 in Epilepsia
Consensus‐based recommendations (CBRs) are essential for health care decision‐making when evidence is limited or conflicting. They can be developed using established methodologies such as the Delphi technique, the nominal group technique (NGT), and the RAND Corporation/University of California Los Angeles (UCLA) Appropriateness Method (RAM). This review explores the advantages and disadvantages of these methods and their applications in epilepsy. A narrative review using PubMed (November 22, 2017 to November 22, 2022) was undertaken examining publications describing Delphi, NGT, and RAM. The frequency of use of each method and their applications in epilepsy care were also reviewed (1966 to October 31, 2023). Sixteen articles were included describing the different consensus‐based methods. The advantages and disadvantages of each method varied widely. The Delphi technique, the most widely used method, emerged as adaptable for instances with limited evidence or impracticality of face‐to‐face interactions. Although NGT favors prompt consensus in single‐session formats, the RAM offers a balanced approach with its hybrid structure. We identified 64 epilepsy studies that used consensus methods, with 58 utilizing the most widely used technique, the Delphi. The Delphi guided consensus mostly for management including for individuals with rare conditions such as myoclonic–atonic seizures or in those with epilepsy and pregnancy. The NGT guided expert consensus on the use of cannabidiol for Dravet and Lennox–Gastaut syndromes and facilitated decision‐making among pharmacy students addressing ethical issues related to patients with epilepsy who drive. The RAM was applied in four studies for its combined individual and group evaluative approach. It was used to develop recommendations or imaging, create quality‐of‐care indicators for infantile spasms, and establish a web‐based tool for assessing surgical candidacy. Consensus methodologies are crucial to inform robust CBR for epilepsy management where clinical practice guidelines are not possible due to limited evidence. The best method depends on the study goal and available resources.
1 October 2026 in Journal of Comparative Effectiveness Research
Aim: Metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD) are progressive liver conditions that can lead to serious long-term outcomes and adverse clinical events. Histologic liver fibrosis is an accepted short-term surrogate end point used in pivotal clinical trials supporting conditionally approved MASH therapies. This study aimed to synthesize up-to-date published associations between histologic liver fibrosis and clinical outcomes, including several novel syntheses. Materials & methods: A systematic literature review identified studies of MASH ± MASLD patients published January 2014 to November 2024 from Ovid MEDLINE ® , Embase and grey literature. Studies reporting hazard ratios (HRs) comparing the risk of relevant major adverse liver outcomes (MALO; e.g., cirrhosis, hepatic decompensation, hepatocellular carcinoma) and mortality by histologic liver fibrosis stage were included in meta-analysis. Pooled estimates were reported as HRs and 95% CIs. Results: Of 2810 returned records, there were 32 eligible studies from 39 articles. Higher fibrosis stage was associated with increased risk of clinical outcomes. Risk of progression to cirrhosis was twofold higher in F3 versus F2 (2.05 [1.45, 2.90]). Risk of hepatic decompensation was >ten-times higher in F3–4 versus F0–2 (10.93 [6.31, 18.92]). Risk of MALO and all-cause mortality were also significantly higher in F4 versus F3 and versus F2, and in F3–4 versus F0–2. Results were directionally consistent among studies of MASH-majority (≥80% MASH) populations and individually reported HRs. Conclusion: Increased clinical risk with more advanced fibrosis and/or cirrhosis among patients with significant liver disease supports the value of histologic liver fibrosis as a short-term surrogate for long-term clinical outcomes.